Form 4: Director Stephen Sherwin Receives NBIX Equity Grant

Neurocrine Biosciences Director Stephen A. Sherwin was granted 2,567 restricted stock units vesting in May 2027.

Summary

• Director Stephen A. Sherwin acquired 2,567 Restricted Stock Units (RSUs) on May 27, 2026.
• Each RSU represents a contingent right to receive one share of Neurocrine Biosciences common stock.
• The grant is subject to a one-year vesting schedule, with full vesting occurring on May 27, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified; this is a standard compensatory equity grant for a board member.

Risks

• None identified; this is a routine disclosure of director compensation.

Future Outlook

The RSUs are scheduled to vest in full on May 27, 2027, at which point the director will receive common stock.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology sector to ensure long-term alignment with corporate performance and shareholder interests.

Comparison to Industry Standards

• The grant size and vesting terms are consistent with standard corporate governance practices for mid-to-large cap biotechnology companies.

Stakeholder Impact

• Minimal impact on shareholders; represents standard director compensation.

Next Steps

• Vesting of the 2,567 RSUs on May 27, 2027.

Key Dates

Keywords

Neurocrine Biosciences, NBIX, Form 4, Insider Trading, Director Compensation, Restricted Stock Units